Aptevo Therapeutics Inc. (APVO): Depreciation & Amortization
$240.0K
Year ended 2025-12-31
$197.0K
Trailing 12 months to 2026-06-30
-35.7%
3-year compound annual growth
-29.8%
5-year compound annual growth
-22.1%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $240.0K | -31.8% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $352.0K | -37.9% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $567.0K | -37.1% | 2025-02-14, From 2023-01-01 |
| 2022-12-31 | $901.0K | -21.2% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $1.14M | -18.6% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $1.41M | -37.1% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $2.23M | -6.5% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $2.39M | -23.6% | 2020-03-25, From 2018-01-01 |
| 2017-12-31 | $3.13M | -7.0% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $3.36M | +15.7% | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | $2.91M | n/a | 2017-03-31, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $240.0K | -31.8% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $71.3K | -38.9% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $723.4K | +142.2% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $138.0K | -67.2% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $663.0K | 0.0% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $1.20M | -7.7% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $15.2K | -97.9% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $318.0K | +3.6% |
| Talphera, Inc. (TLPH) | 2024-12-31 | $0 | -100.0% |
Compare APVO, HURA, SKYE, BFRI side by side · Screen every company in Pharmaceutical Preparations ↗